Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 1/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 14/20 | 0.78 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8989420 | 0.94 | CACNA1C (0.79) | CACNA1COPRM1OPRD1OPRK1 | |
| SCHEMBL8989346 | 0.93 | OPRM1 (0.80) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL17874058 | 0.92 | CACNA1C (1.00) | CACNA1COPRM1OPRD1OPRK1 | |
| SCHEMBL21960081 | 0.92 | CACNA1C (0.84) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL36652 | 0.92 | CACNA1C (1.00) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL41242 | 0.91 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL3711219 | 0.91 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL29846323 | 0.91 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL3423820 | 0.91 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| SCHEMBL11563541 | 0.91 | OPRM1 (0.82) | CACNA1COPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10420729-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2019-09-24 | — | — | US | claimed |
| EP-2968129-A1 | ABUSE RESISTANT CAPSULE | R.P. Scherer Technologies, LLC (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014140231-A1 | ABUSE RESISTANT CAPSULE | WENGNER SIMONE (DE) | 2014-09-18 | — | — | WO | claimed |
| EP-1558257-B1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | GRUENENTHAL GMBH (DE) | 2013-12-25 | — | — | EP | claimed |
| EP-1560585-B1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | GRUENENTHAL GMBH (DE) | 2012-08-01 | — | — | EP | claimed |
| EP-1515702-B1 | ABUSE-PROTECTED ADMINISTRATION FORM | GRUENENTHAL GMBH (DE) | 2008-10-15 | — | — | EP | claimed |
| EP-1558221-B1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | GRUENENTHAL GMBH (DE) | 2007-06-06 | — | — | EP | claimed |
| US-20050214223-A1 | Abuse-safeguarded dosage form | GRUENENTHAL GMBH (DE) | 2005-09-29 | — | — | US | claimed |
| EP-0383579-B1 | N-Phenyl-N-(4-piperidinyl)amides useful as analgesics | GLAXO WELLCOME INC (US) | 1996-07-17 | — | — | EP | claimed |
| US-5466700-A | Anesthetic use of N-phenyl-N-(4-piperidinyl)amides | GLAXO WELLCOME INC. (US) | 1995-11-14 | — | — | US | claimed |
| US-5019583-A | N-phenyl-N-(4-piperidinyl)amides useful as analgesics | GLAXO INC. (US) | 1991-05-28 | — | — | US | claimed |
| EP-0383579-A1 | N-Phenyl-N-(4-piperidinyl)amides useful as analgesics | GLAXO WELLCOME INC. (US) | 1990-08-22 | — | — | EP | claimed |
| US-11844865-B2 | Abuse-proofed oral dosage form | Grünenthal GmbH (DE) | 2023-12-19 | — | — | US | disclosed |
| US-20230390210-A1 | MODIFIED RELEASE SOFTGEL CAPSULES | R.P. SCHERER TECHNOLOGIES, LLC | 2023-12-07 | — | — | US | disclosed |
| EP-4228597-A1 | MODIFIED RELEASE SOFTGEL CAPSULES | R.P. Scherer Technologies, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230126276-A1 | FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING | ALLEGHENY-SINGER RESEARCH INSTITUTE | 2023-04-27 | — | — | US | disclosed |
| US-5466700-A | Anesthetic use of N-phenyl-N-(4-piperidinyl)amides | GLAXO WELLCOME INC. (US) | 1995-11-14 | — | — | US | disclosed |
| EP-0638554-A1 | Process for producing a N-phenyl-N-(4-piperidinyl) amide derivative | GLAXO GROUP LIMITED (GB) | 1995-02-15 | — | — | EP | disclosed |
| US-5019583-A | N-phenyl-N-(4-piperidinyl)amides useful as analgesics | GLAXO INC. (US) | 1991-05-28 | — | — | US | disclosed |
| EP-0383579-A1 | N-Phenyl-N-(4-piperidinyl)amides useful as analgesics | GLAXO WELLCOME INC. (US) | 1990-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126276-A1 | FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING | OPRK1, OPRL1, OPRM1 | CACNA1C 1472/4885OPRM1 3/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.